Cumberland Pharmaceuticals (NASDAQ:CPIX) Share Price Crosses Above 200 Day Moving Average – Time to Sell?

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $4.28 and traded as high as $6.87. Cumberland Pharmaceuticals shares last traded at $6.48, with a volume of 38,864 shares trading hands.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Wall Street Zen lowered shares of Cumberland Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Cumberland Pharmaceuticals currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Down 5.3%

The company has a debt-to-equity ratio of 0.25, a current ratio of 0.95 and a quick ratio of 0.79. The stock has a market capitalization of $97.07 million, a P/E ratio of -13.22 and a beta of 0.09. The firm has a 50 day moving average of $5.24 and a 200-day moving average of $4.28.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The company had revenue of $9.13 million during the quarter, compared to the consensus estimate of $8.50 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new position in Cumberland Pharmaceuticals in the second quarter worth $34,000. Arrowstreet Capital Limited Partnership bought a new stake in Cumberland Pharmaceuticals in the 1st quarter valued at $66,000. Two Sigma Investments LP raised its stake in shares of Cumberland Pharmaceuticals by 16.5% in the 3rd quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 5,326 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Cumberland Pharmaceuticals in the 4th quarter valued at $192,000. Finally, Geode Capital Management LLC lifted its holdings in shares of Cumberland Pharmaceuticals by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock worth $427,000 after acquiring an additional 5,653 shares during the period. 15.51% of the stock is owned by institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.